CD274 and extranodal nasal NK/T cell lymphoma: In a single-arm phase 2 trial in 80 patients with r/r NKTCL, the anti-PD-L1 mAb sugemalimab demonstrated 46.2% ORR, 30.4% CR rate, 68.6% 1-year OS rate and 54.6% 2-year OS rate [61, 62].